Rick DeLuca is executive vice president and president, Animal Health for Merck.​ Rick has worldwide responsibility for the Animal Health business, a position he has held since 2011. Under Rick’s leadership, Merck’s Animal Health business has become an industry leader that offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products.

Prior to joining Merck, Rick spent more than two decades in positions of increasing scope and responsibility at Wyeth, including president of Animal Health, chief operating officer and chief financial officer of Animal Health, vice president of finance global pharmaceuticals and director audit. He was also a member of Wyeth’s executive, operations, law and regulatory and human resources and benefits committees.​

Rick was board chairman of Health for Animals, the global animal health industry association, from 2017 to 2020. He is also board chairman of Animal Health Institute, the U.S. animal medicines industry association, a position he has held since 2016. ​Rick received his B.A. in business administration from Widener University. He is a certified public accountant and certified management accountant.

Rob Davis is chairman of the board and chief executive officer of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021, CEO and a member of the board of directors on July 1, 2021, and chairman of the board on December 1, 2022.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s medical products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation, one of America’s largest energy holding companies, and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a member of the Northwestern Law Board at the Northwestern University Pritzker School of Law. He is also a board member of Project HOPE, a nonprofit organization focused on empowering health care workers to deliver expert care when and where it is needed most, and of Catalyst, a global nonprofit that promotes equal access to career opportunities and corporate leadership for women.

Rob received his J.D. from the Northwestern University Pritzker School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

Sanat Chattopadhyay is executive vice president and president, Merck Manufacturing Division. He has responsibility for the company’s worldwide manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines, biologics and animal health products.

A proven leader in the biopharmaceutical industry, Sanat joined Merck in November 2009 as senior vice president of global vaccines and sterile manufacturing operations, spearheading the transformation of manufacturing and supply chain to grow and globalize its vaccine business. Under Sanat’s leadership, Merck is currently executing significant expansion of its biologics and vaccines manufacturing capacity to reach more patients around the globe.

Before joining Merck, he served as senior vice president, technical operations and product supply, for Wyeth Pharmaceuticals, with responsibility for product supply, process development and operational excellence. Previously, he worked at Aventis and its predecessor companies as senior vice president, industrial operations, having served in many positions with increasing responsibilities for global supply chain, technology and manufacturing sites across North America, Europe and Asia Pacific.

A graduate chemical engineer from Jadavpur University and post-graduate industrial engineer from NITIE, India, Sanat is widely travelled, having lived with his family in five countries across three continents.